Biodiem And Nobilon Join Top Us Science Facility In Race To Develop Bird Flu Vaccine (Medical News Today) In a major boost to the fight against the world bird flu pandemic threat, Melbourne based pharmaceutical development company BioDiem Ltd (ASX:BDM) today announced it had signed a cooperative research and development agreement (CRADA) with the US Centers for Disease Control and Prevention (CDC) to develop a cell culture candidate vaccine against avian influenza H5N1. [click link for full article] [News Source]